Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07528430) titled 'Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer' on April 7.
Study Type: Observational
Primary Sponsor: University of Maryland, Baltimore
Condition:
Pancreatic Cancer, Advanced or Metastatic
Recruitment Status: Not recruiting
Date of First Enrollment: May 1, 2026
Target Sample Size: 450
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07528430
Disclaimer: Curated by HT Syndication....